↓ Skip to main content

Biological Predictors of Clozapine Response: A Systematic Review

Overview of attention for article published in Frontiers in Psychiatry, July 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter
16 X users

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
123 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Biological Predictors of Clozapine Response: A Systematic Review
Published in
Frontiers in Psychiatry, July 2018
DOI 10.3389/fpsyt.2018.00327
Pubmed ID
Authors

Ruta Samanaite, Amy Gillespie, Kyra-Verena Sendt, Grant McQueen, James H. MacCabe, Alice Egerton

Abstract

Background: Clozapine is the recommended antipsychotic for treatment-resistant schizophrenia (TRS) but there is significant variability between patients in the degree to which clozapine will improve symptoms. The biological basis of this variability is unknown. Although clozapine has efficacy in TRS, it can elicit adverse effects and initiation is often delayed. Identification of predictive biomarkers of clozapine response may aid initiation of clozapine treatment, as well as understanding of its mechanism of action. In this article we systematically review prospective or genetic studies of biological predictors of response to clozapine. Methods: We searched the PubMed database until 20th January 2018 for studies investigating "clozapine" AND ("response" OR "outcome") AND "schizophrenia." Inclusion required that studies examined a biological variable in relation to symptomatic response to clozapine. For all studies except genetic-studies, inclusion required that biological variables were measured before clozapine initiation. Results: Ninety-eight studies met the eligibility criteria and were included in the review, including neuroimaging, blood-based, cerebrospinal fluid (CSF)-based, and genetic predictors. The majority (70) are genetic studies, collectively investigating 379 different gene variants, however only three genetic variants (DRD3 Ser9Gly, HTR2A His452Tyr, and C825T GNB3) have independently replicated significant findings. Of the non-genetic variables, the most consistent predictors of a good response to clozapine are higher prefrontal cortical structural integrity and activity, and a lower ratio of the dopamine and serotonin metabolites, homovanillic acid (HVA): 5-hydroxyindoleacetic acid (5-HIAA) in CSF. Conclusions: Recommendations include that future studies should ensure adequate clozapine trial length and clozapine plasma concentrations, and may include multivariate models to increase predictive accuracy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 123 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 15%
Student > Ph. D. Student 15 12%
Student > Master 13 11%
Student > Doctoral Student 11 9%
Student > Postgraduate 8 7%
Other 27 22%
Unknown 31 25%
Readers by discipline Count As %
Medicine and Dentistry 26 21%
Neuroscience 12 10%
Pharmacology, Toxicology and Pharmaceutical Science 10 8%
Psychology 9 7%
Biochemistry, Genetics and Molecular Biology 7 6%
Other 19 15%
Unknown 40 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2019.
All research outputs
#4,650,203
of 25,708,267 outputs
Outputs from Frontiers in Psychiatry
#2,567
of 12,875 outputs
Outputs of similar age
#80,949
of 342,311 outputs
Outputs of similar age from Frontiers in Psychiatry
#68
of 175 outputs
Altmetric has tracked 25,708,267 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,875 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.4. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,311 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 175 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.